Search
Parkinson's Disease Paid Clinical Trials in Florida
A listing of 36 Parkinson's Disease clinical trials in Florida actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 36
The state of Florida currently has 36 active clinical trials seeking participants for Parkinson's Disease research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Parkinson's Disease: Genetic Testing and Clinical Trial
Recruiting
Sano is launching a new study to understand the genetics of Parkinson’s and give researchers the data they need to better understand this condition. By participating, you will support cutting-edge research and help pave the way for future breakthroughs. You may be referred to participate in a clinical trial.
By participating in this study, you can:
- Receive a first-of-its-kind, Parkinson's genetic test at home, cost free
- Understand your eligibility for an investigational clinical trial in Parkinson's disease
- Receive notifications for future research opportunities
- Access expert, condition-specific educational materials tailored to Parkinson's disease
By participating in this study, you can:
- Receive a first-of-its-kind, Parkinson's genetic test at home, cost free
- Understand your eligibility for an investigational clinical trial in Parkinson's disease
- Receive notifications for future research opportunities
- Access expert, condition-specific educational materials tailored to Parkinson's disease
Conditions:
Parkinson's Disease
Parkinson Disease
Parkinson's Disease (PD)
Idiopathic Parkinson's Disease
Parkinsonian Disorders
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Recruiting
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/30/2025
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
Recruiting
The objectives of this study are to collect the long-term safety and effectiveness data of performing thalamotomy for tremor dominant Parkinson's Disease (TDPD) using the Exablate Neuro system.
Gender:
ALL
Ages:
Between 30 years and 99 years
Trial Updated:
04/29/2025
Locations: Miami Neuroscience Institute Baptist Health, Miami, Florida
Conditions: Tremor Associated With Tremor Dominant Parkinson's Disease
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
Recruiting
This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
04/29/2025
Locations: Institute for Neuroimmune Medicine, Davie, Florida +1 locations
Conditions: Parkinson Disease
Studies of the Variable Phenotypic Presentations of Rapid-Onset Dystonia Parkinsonism and Other Movement Disorders
Recruiting
The purposes of this study are to identify persons with rapid-onset dystonia-parkinsonism (RDP) or mutations of the RDP gene, document prevalence of the disease, and map its natural history.
Gender:
ALL
Ages:
All
Trial Updated:
04/28/2025
Locations: University of Miami, Miami, Florida
Conditions: Dystonia, Parkinsonism
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
Recruiting
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Visionary Investigators Network, Aventura, Florida +1 locations
Conditions: Parkinson Disease
A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Recruiting
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 50-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.
Participants will:
• Take NEU-411 or placebo every day for 52 weeks
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
04/25/2025
Locations: Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida +2 locations
Conditions: Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
Recruiting
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Gender:
ALL
Ages:
Between 45 years and 75 years
Trial Updated:
04/21/2025
Locations: Parkinson's Disease and Movement Disorders Center of Boca Raton (Neurology), Boca Raton, Florida +1 locations
Conditions: Parkinson Disease
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
Recruiting
This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
04/21/2025
Locations: Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida
Conditions: Parkinson Disease
A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
Recruiting
This trial is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety/tolerability, PK, and pharmacodynamics of VENT 02, administered orally at 1 dose level twice daily (BID) over 28 days in patients with mild to moderate Parkinson's disease.
The study includes a screening period, a 28-day double-blind treatment period, and a 7-day follow-up period after last dose.
Approximately 30 patients will be randomized into 1 of the 2 treatment arms.
Gender:
ALL
Ages:
Between 45 years and 90 years
Trial Updated:
04/21/2025
Locations: Investigative Site, Aventura, Florida +11 locations
Conditions: Parkinson Disease
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
Recruiting
The primary objective of this study is to characterize real-world clinical outcomes of Deep Brain Stimulation (DBS) using retrospective review of de-identified patient records.
Gender:
ALL
Ages:
All
Trial Updated:
04/09/2025
Locations: University of Miami Hospital, Miami, Florida +1 locations
Conditions: Parkinson Disease, Essential Tremor, Dystonia
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
Recruiting
Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogeni... Read More
Gender:
ALL
Ages:
Between 35 years and 80 years
Trial Updated:
04/09/2025
Locations: K2 Medical Research, 101 Southhall Lane, Suite 150, Maitland, Florida +1 locations
Conditions: Parkinson Disease
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Recruiting
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.
The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.
Additionally, the utilization of the DBS Illumina 3D feature that may be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: University of Florida Shands Hospital, Gainesville, Florida +4 locations
Conditions: Parkinson's Disease
1 - 12 of 36